Additional file 4 of RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers

Additional file 4: Fig. S4. Flow cytometry analysis of 8-074 treated tumors. (a) FACS analysis of Treg from LLC tumor-bearing mice in Figure 3B for the vehicle group and 8-074 (50 mg/kg) group. Representative flow panels from CD45+ CD3+ CD4+ CD8- FOXP3+ T cells (Treg) are shown. (b) Statistical results of FCM analysis in LLC tumors. The ratio of Treg in the CD3+ cell populations and the CD8/Treg ratio in LLC tumors are shown (***P < 0.001 and ****P < 0.0001). (c) Relative mRNA expression of Ifn-γ in LLC tumors as determined by qPCR. N = 3 per group, **P < 0.01, by Student’s t-test. (d) ELISA assayed IFN-γ levels in LLC tumors (N = 3 per group, **P < 0.01, ***P < 0.001, by Student’s t-test). Data shown are mean ± SD of tumor volume for each group (N = 4 – 5 per group, *P < 0.05, **P < 0.01, *** P < 0.001 and **** P < 0.0001, by Student’s t-test). Data represents the mean ± SD from biological quadruplicates. All error bars represent the mean ± SD. Data are from three independent experiments.